pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
553
stories
Aug 31, 26
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
Aug 29, 26
STAT+: A Novartis drug cut inflammation. Can it improve heart outcomes?
stat
Aug 29, 26
#ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo's failure
endpoints
Aug 28, 26
Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio
biospace
Aug 28, 26
Roche bets $1B+ on DualityBio's ADC tech to tackle TOPO1 resistance
endpoints
Aug 28, 26
Multispecifics are transforming the CDMO development architecture
biospace
Aug 28, 26
Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
fiercebiotech
Aug 27, 26
New data could widen use of AstraZeneca, Amgen immune disease drug
biopharma dive
Aug 27, 26
Q&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal
endpoints
Aug 27, 26
Generate Bio drops as data accidentally leaked ahead of European conference
biospace
Aug 27, 26
AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis
biospace
Aug 27, 26
Osivax bags flu vaccine rights to pursue combination shot vision
fiercebiotech
Aug 27, 26
CAR Ts will only treat autoimmune diseases if we can scale delivery
biospace
Aug 27, 26
Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
biospace
Aug 26, 26
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
biopharma dive
Aug 26, 26
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
biospace
Aug 26, 26
Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
biospace
Aug 26, 26
Akeso, Summit hail ivonescimab's biliary tract cancer win in China-only Phase 3 trial
endpoints
Aug 26, 26
Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data
endpoints
Aug 26, 26
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
fiercebiotech
Aug 26, 26
Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data
fiercebiotech
Aug 25, 26
New Jazz cancer drug approval could drive blockbuster sales
biopharma dive
Aug 25, 26
J&J’s Imaavy wins label expansion; Two approvals in Japan
endpoints
Aug 25, 26
FDA approves Jazz's Ziihera in frontline gastric cancer
endpoints
Aug 24, 26
Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
fiercebiotech
Aug 21, 26
Shareholder pressures Capricor; Lilly dives deeper into vaccines
biopharma dive
Aug 20, 26
Regeneron to challenge Ipsen as FDA clears bone disease drug
biopharma dive
Aug 20, 26
Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’
fiercebiotech
Aug 20, 26
Chutes & Ladders—Neumora shuffles leadership ahead of IND
fiercebiotech
Aug 20, 26
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
biospace
← prev
page 7 of 19
next →
